Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

Chart review of records of patients treated for betel nut-induced oral cancer with pembrolizumab and cetuximab.

Completed

Looking for future studies?

Key information

Conditions

Oral Squamous Cell Carcinoma (OSCC) Carcinoma Carcinoma, Squamous Cell Head and Neck Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Squamous Cell Carcinoma of Head and Neck

Sex eligibility

All sexes

Study type

Observational

Primary location

CHCC

Saipan, MP, 96950, Northern Mariana Islands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Advanced betel nut-induced oral cancer

Exclusion criteria

None

Treatment and study plan

pembrolizumab and cetuximab

Drug

Treatment of betel nut-induced oral cancer with pembrolizumab and cetuximab

Primary outcomes

Objective Response Rate (ORR)

Time frame: From date first treatment received until 3 months later

Assessed by clinical measurement of largest tumor size

Sponsors and collaborators

Lead sponsor

Commonwealth Healthcare Corporation

Other

Registry information

Important dates

Study start: 2020
Primary completion: 2024
Study completion: 2024
First posted: Jun 11, 2025
Registry last updated: Jun 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting